文献速递其他结缔组织病

干燥综合征的新兴治疗:有望上市的靶向药物

Emerging treatments for Sjögren's disease: promising drugs on the horizon.
PubMed 文献 · RMD Open · 2026-06-24

本文综述干燥综合征(SjD)的免疫发病机制与新兴靶向治疗方向。目前尚无改善病情的药物获批,治疗以对症为主;针对B细胞存活与信号、IgG再循环、细胞内激酶通路及共刺激相互作用的靶向策略在II/III期研究中显示一定疗效,但多集中于中重度系统性疾病患者。

要点

  • 干燥综合征尚无改善病情药物获批,现有治疗以对症为主
  • 靶向B细胞、干扰素、激酶通路及共刺激分子是主要研发方向
  • 需完善疗效评价指标与患者分层以推进个体化治疗

核心结论

  • 干燥综合征尚无改善病情疗法获批,新兴靶向治疗在II/III期研究中显示一定疗效,但主要针对中重度系统性疾病患者。

研究设计与样本

  • 本文为综述,围绕干燥综合征免疫发病机制及新兴靶向治疗药物进行总结(摘要未报告具体检索范围)。

主要发现

  • 发病机制涉及上皮细胞活化、干扰素驱动炎症、B细胞过度活化及T细胞失调。
  • 新兴策略包括调节B细胞存活与信号、抑制IgG再循环与细胞内激酶通路、阻断免疫细胞共刺激相互作用。
  • 近期II/III期研究显示令人鼓舞的疗效迹象,但主要集中于中重度系统性疾病患者。

临床怎么用

  • 对以腺体症状为主或系统活动度低的患者,现有靶向治疗证据不足,仍需对症管理。
  • 临床应关注患者分层与疗效评价指标的完善,以推动个体化治疗。

局限性

  • 摘要未报告具体研究设计细节、样本量及疗效数值。
  • 现有研究多集中于中重度系统性疾病患者,对腺体型或低系统活动度人群代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sjögren's disease (SjD) is a chronic, multisystem autoimmune disorder characterised by lymphocytic infiltration of exocrine glands, leading to dryness, fatigue and variable extraglandular involvement. Despite its significant clinical and socioeconomic burden, no disease-modifying therapies have yet been approved. Current management remains largely symptomatic, reflecting the complexity and heterogeneity of the disease and the limitations of past clinical trials. Recent advances in the understanding of SjD immunopathogenesis have clarified key mechanisms including epithelial activation, interferon-driven inflammation, B-cell hyperactivity and T-cell dysregulation. These insights have fuelled the development of targeted therapies designed to modulate specific immune pathways, aiming to interrupt the self-perpetuating cycle of epithelial injury and immune activation. Emerging strategies include the modulation of B-cell survival and signalling, inhibition of IgG recycling and intracellular kinase pathways and blockade of co-stimulatory interactions between immune cells. Although recent phase II and phase III studies have shown encouraging signs of efficacy, they have largely focused on patients with moderate-to-severe systemic disease. Addressing the unmet therapeutic need in individuals with predominantly glandular or low systemic activity remains a major challenge. Continued refinement of outcome measures and patient stratification will be essential to translate mechanistic advances into effective, personalised treatments capable of altering the natural course of SjD.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Marques-Gomes C, Bowman SJ, Nayar S, et al. Emerging treatments for Sjögren's disease: promising drugs on the horizon. RMD Open. 2026. PMID: 42342283. doi:10.1136/rmdopen-2024-004310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。